AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$54.53
-0.26 (-0.47%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$54.79
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
29,258

10-day average volume:
5,574,523
29,258

LAWSUITS FILED AGAINST SLQT, SPPI and EAR - Jakubowitz Law Pursues Shareholders Claims

12:50 pm ET October 12, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 12, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Selectquote, Inc. (NYSE:SLQT)

CONTACT JAKUBOWITZ ABOUT SLQT:

https://claimyourloss.com/securities/selectquote-inc-loss-submission-form/?id=20348&from=1

Class Period : May 20, 2020 - August 25, 2021

Lead Plaintiff Deadline : October 15, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

CONTACT JAKUBOWITZ ABOUT SPPI:

https://claimyourloss.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=20348&from=1

Class Period : December 27, 2018 - August 5, 2021

Lead Plaintiff Deadline : November 1, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Eargo, Inc. (NASDAQ:EAR)

CONTACT JAKUBOWITZ ABOUT EAR:

https://claimyourloss.com/securities/eargo-inc-loss-submission-form/?id=20348&from=1

Class Period : October 16, 2020 - September 22, 2021

Lead Plaintiff Deadline : December 6, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Eargo had improperly sought reimbursements from certain third-party payors; (2) the foregoing was reasonably likely to lead to regulatory scrutiny; (3) as a result and because the reimbursements at issue involved the Company's largest third-party payor, Eargo's financial results would be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Image: https://www.accesswire.com/users/newswire/images/667772/Jakubowitz_CTA-1.png

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW

1140 Avenue of the Americas

9th Floor

New York, New York 10036

T: (212) 867-4490

F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:

https://www.accesswire.com/667772/LAWSUITS-FILED-AGAINST-SLQT-SPPI-and-EAR--Jakubowitz-Law-Pursues-Shareholders-Claims

comtex tracking

COMTEX_395036995/2457/2021-10-12T12:50:37

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.